Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.
- DOI
- 10.1016/j.jns.2019.08.004
- Published
- 2019 Dec 15
- Container
- Journal of the neurological sciences
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jns.2019.08.004,
title = {Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.},
author = {Murai H and Uzawa A and Suzuki Y and Imai T and Shiraishi H and Suzuki H and Okumura M and O'Brien F and Wang JJ and Fujita KP and Utsugisawa K and REGAIN Study Group},
year = {2019},
journal = {Journal of the neurological sciences},
doi = {10.1016/j.jns.2019.08.004},
url = {https://doi.org/10.1016/j.jns.2019.08.004}
}RIS
TY - JOUR TI - Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. AU - Murai H AU - Uzawa A AU - Suzuki Y AU - Imai T AU - Shiraishi H AU - Suzuki H AU - Okumura M AU - O'Brien F AU - Wang JJ AU - Fujita KP AU - Utsugisawa K AU - REGAIN Study Group PY - 2019 JO - Journal of the neurological sciences DO - 10.1016/j.jns.2019.08.004 UR - https://doi.org/10.1016/j.jns.2019.08.004 ER -
APA
H, M., A, U., Y, S., T, I., H, S., H, S., M, O., F, O., JJ, W., KP, F., K, U., & Group, R. S. (2019). Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.. Journal of the neurological sciences. https://doi.org/10.1016/j.jns.2019.08.004
Source records
- pubmed · retrieved 2026-09-27T09:27:24.544Z